Skip to content
Search

Latest Stories

Vaccination reduces risk of COVID-19 death but protection wanes after 6 months: UKHSA study

Vaccination reduces risk of COVID-19 death but protection wanes after 6 months: UKHSA study

Case fatality risk of COVID-19 was 10 times higher in unvaccinated adults compared to those who received the vaccine within six months prior to testing positive

A new study has revealed that the risk of death from COVID-19 decreases significantly after vaccination, but this protection diminishes after six months, providing evidence for continued booster doses.


Researchers from the UK Health Security Agency (UKHSA), who analysed more than 10 million cases of COVID-19 in adults in England between May 2020 and February 2022, found a clear association between vaccination and reduced mortality.

But they also highlighted a crucial timeframe - within six months of the last vaccine dose – when Case Fatality Risk (CFR) - the proportion of cases that resulted in death - was consistently at its lowest across all age groups. After this, the protective benefit of the vaccine began to wane and CFR increased.

Among adults over 50 years, CFR was 10 times higher in the unvaccinated individuals (6.3 per cent) compared to those who had been vaccinated within six months prior to testing positive (0.6 per cent).

The study also found a steep decline in COVID-19 CFR in early 2021, aligning with the initial vaccine rollout.

Florence Halford from the UKHSA’s COVID-19 Vaccines and Epidemiology Division said: "COVID-19 Case Fatality Risk reduced after vaccination, with the lowest seen across all age bands when vaccinated up to six months prior to the specimen date. This provides some evidence for continued booster doses in older age groups."

Their findings have been published in the Journal of the Royal Society of Medicine (JRSM).

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less